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Abstract
Background: In the new pathologic classification of lung adenocarcinoma proposed by IASLC/ATS/ERS in 2011,
lepidic type adenocarcinomas are constituted by three subtypes; adenocarcinoma in situ (AIS), minimally invasive
adenocarcinoma (MIA) and lepidic predominant invasive adenocarcinoma (LPIA). Although these subtypes are
speculated to show sequential progression from preinvasive lesion to invasive lung cancer, changes of protein
expressions during these processes have not been fully studied yet. This study aims to glimpse a proteomic view of
the early lepidic type lung adenocarcinomas.
Methods: A total of nine formalin-fixed and paraffin-embedded (FFPE) lepidic type lung adenocarcinoma tissues
were selected from our archives, three tissues each in AIS, MIA and LPIA. The tumor and peripheral non-tumor cells
in these FFPE tissues were collected with laser microdissection (LMD). Using liquid chromatography-tandem mass
spectrometry (MS/MS), protein compositions were compared with respect to the peptide separation profiles among
tumors collected from three types of tissues, AIS, MIA and LPIA. Proteins identified were semi-quantified by spectral
counting-based or identification-based approach, and statistical evaluation was performed by
pairwise G-tests.
Results: A total of 840 proteins were identified. Spectral counting-based semi-quantitative comparisons of all
identified proteins through AIS to LPIA have revealed that the protein expression profile of LPIA was significantly
differentiated from other subtypes. 70 proteins including HPX, CTTN, CDH1, EGFR, MUC1 were found as LPIA-type
marker candidates, 15 protein candidates for MIA-type marker included CRABP2, LMO7, and RNPEP, and 26 protein
candidates for AIS-type marker included LTA4H and SOD2. The STRING gene set enrichment resulted from the
protein-protein interaction (PPI) network analysis suggested that AIS was rather associated with pathways of focal
adhesion, adherens junction, tight junction, that MIA had a strong association predominantly with pathways of
proteoglycans in cancer and with PI3K-Akt. In contrast, LPIA was associated broadly with numerous
tumor-progression pathways including ErbB, Ras, Rap1 and HIF-1 signalings.
Conclusions: The proteomic profiles obtained in this study demonstrated the technical feasibility to elucidate
protein candidates differentially expressed in FFPE tissues of LPIA. Our results may provide candidates of
disease-oriented proteins which may be related to mechanisms of the early-stage progression of lung
adenocarcinoma.
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Background
Lung cancer is the leading cause of cancer-related mor-
tality worldwide [1]. In Japan, annual deaths from lung
cancer are increasing and currently approach about
70,000 [2], while in the United States with a recent de-
creasing trend in mortality, more than 160,000 succumb
annually [3]. In an increasing trend worldwide, advances
in chest high-resolution computed tomography (HRCT)
scanning technology have enabled the localization of
small adenocarcinoma nodules [4] at an earlier and
potentially more curable stage of development than pre-
viously possible [5]. There are 90 million current and
ex-smokers in the United States who are at increased
risk of lung cancer. The published data from the
National Lung Screening Trial (NLST) suggest that
yearly screening with low-dose thoracic CT scan in
heavy smokers can reduce lung cancer mortality by 20 %
and all-cause mortality by 7-% [6].
In 2011, the new pathologic classification of lung adeno-
carcinoma was proposed by the International Association
for the Study of Lung Cancer (IASLC), the American
Thoracic Society (ATS) and the European Respiratory So-
ciety (ERS) [7]. In the new classification, the concept of
adenocarcinoma in situ (AIS) and minimally invasive
adenocarcinoma (MIA) were newly introduced and the
term bronchioloalveolar carcinoma (BAC) was abolished.
Additionally, invasive adenocarcinomas were categorized
into 6 subtypes, lepidic, acinar, papillary, micropapillary,
solid, and variants, according to the predominant histo-
logic pattern. Both AIS and MIA were defined as tumors ≤
3 cm in size. AIS is a preinvasive lesion showing pure le-
pidic growth without invasion. MIA is also lepidic pre-
dominant tumor but with ≤ 5 mm invasion. LPIA is an
invasive adenocarcinoma showing former nonmucinous
BAC pattern with > 5 mm invasion. These 3 lepidic type
adenocarcinomas are speculated to show step-wise
progression from AIS, MIA, to LPIA. After complete re-
section of AIS or MIA, usually 100 % of recurrence-free
5-year survival can be obtained [7], while some recurrent
cases are found after resection of LPIA [8–10]. Since post-
operative prognoses between the AIS plus MIA group and
LPIA are different, differential protein expressions associ-
ated with invasiveness of cancer cells in each subtype
should play important roles to determine local recur-
rences and survivals. However, precise proteomic analyses
using individual cells in these early adenocarcinomas have
not yet been performed. To the best of our knowledge,
this is the first report performing proteomic analysis using
micro-dissected early phase lung adenocarcinoma cells.
Recent advancements in shotgun sequencing and quan-
titative mass spectrometry for protein analyses could
make proteomics amenable to clinical biomarker discov-
ery [11, 12]. Laser microdissection (LMD) made it possible
to collect target cells from a variety of formalin fixed
paraffin embedded (FFPE) cancer tissues. This study at-
tempts to capture a proteomic view of LPIA in compari-
son with other early stage lung adenocarcimomas by
utilizing a label-free identification-based (or spectral
counting-based) semi-quantitative shotgun proteomics ap-
proach following LMD [13–19].
Results and discussion
Group comparisons by Rsc and G-statistics
We used Abacus [20] to select high-scoring proteins
using the thresholds of PeptideProphet probability > 0.99
and ProteinProphet probability > 0.9 as described in
“MATERIALS and METHODS”, resulting in identifying
a total of 840 proteins and obtaining their values of raw
fold change in log2 (Rsc). For G-test (p < 0.05) [21], the
raw SpCs of all patients in each group were pooled,
thereby improving the performance of G-test and de-
creasing false positive rates significantly [15, 22]. Next,
the values of Rsc that is a measure of fold changes for
protein expression levels were calculated as described in
“Materials and Methods” using the spectral counts of
these proteins.
The full lists of 840 proteins identified were provided as
Additional file 1: Table S3. Proteins in LPIA, MIA and
AIS identified under SpCtotal > 2 for a protein were 789,
607, and 544, respectively, and were subjected to gene
ontology (GO) analysis by using PANTHER Ver. 10.0
(http://www.pantherdb.org/). Results of (A) biological pro-
cesses and (B) protein classes are shown in Fig. 1.
A marker candidate for the LPIA-type was chosen under
the following criterions so that a protein had the pairwise
p-value < 0.05 in G-test and Rsc < −1 against MIA and AI,
[LPIA] (the retative abundance in spectral count) higher
than [MIA] and [AIS], and total spectral counts throughout
the desease states > 5. Table 1 summarizes 70 protein candi-
dates thus obtained for LPIA from total 840 proteins identi-
fied, which are listed in increasing order of the Rsc (LPIA
vs. MIA) values; the negatively larger the Rsc value of a
given protein, the greater its expression level in LPIA com-
pared with MIA and AIS. Those included beta-actin-like
protein 2 (ACTBL2), tubulin alpha-1C chain (TUBA1C),
band 7 protein family protein, HLA class I histocompatibil-
ity antigen, A-2 alpha chain (HLA-A), ARPC4-TTLL3 fu-
sion protein, epiplakin (EPPK1), synaptogyrin-2 (SYNGR2),
hemopexin (HPX), small nuclear ribonucleoprotein G-like
protein (SNRPF), src substrate cortactin (CTTN), cadherin-
1 (CDH1) (known as E-cadherin), epidermal growth factor
receptor (EGFR), mucin-1 (MUC1), and promyelocytic
leukemia protein (PML). The high expression of beta-actin-
like protein 2 (ACTBL2) and tubulin alpha-1C chain
(TUBA1C) might be related to active actin polymerization
associated with invasiveness of LPIA.
Src substrate cortactin (CTTN), epidermal growth fac-
tor receptor (EGFR) and mucin-1 (MUC1) expressed in
Kato et al. Clinical and Translational Medicine  (2015) 4:24 Page 2 of 13
LPIA might reflect its invasiveness with aggressive prolifer-
ation. Invasive carcinoma cells degrade and invade through
the extracellular matrix (ECM) by invadopodia, where an
EGFR–Src–Arg–cortactin pathway is considered to medi-
ate functional maturation of invadopodia [23–25]. Overex-
pression of cortactin protein (CTTN) has been currently
considered to be an important biomarker for invasive can-
cers because of its frequent link to various invasive cancers,
including melanoma, colorectal, and glioblastoma [25].
Proteins expressed increasingly along the disease stages
from AIS to LPIA, which might be considered to be disease
progression-related, included were alpha-enolase (ENO1),
plectin (PLEC), major vault protein (MVP), heterogeneous
nuclear ribonucleoprotein M (HNRNPM), 14-3-3 protein
sigma (SFN), lysophosphatidylcholine acyltransferase 1
(LPCAT1), anterior gradient protein 2 homolog (AGR2),
phospholipase D3 (PLD3), hypoxia up-regulated protein 1
(HYOU1), fatty acid synthase (FASN), programmed cell
death protein 6 (PDCD6), and ethylmalonyl-CoA decarb-
oxylase (ECHDC1). Among proteins expressed characteris-
tically in the AIS and MIA disease stages, leukotriene A-4
hydrolase (LTA4H) in AIS and cellular retinoic acid-binding
protein 2 (CRABP2) in MIA, respectively, were representa-
tive. Proteins significant to AIS and MIA are provided in
Additional file 1: Table S1 and S2. Enhanced AGR2 expres-
sion has been observed in most human adenocarcinomas,
Fig. 1 Gene ontology (GO) analysis for three cancer groups, AIS, MIA and LPIA, in which utilized were 544, 607, and 789 proteins, respectively,
identified with SpC > 2. a Biological process: 1, cellular component organization or biogenesis (GO:0071840); 2, cellular process (GO:0009987); 3,
localization (GO:0051179); 4, apoptotic process (GO:0006915); 5, reproduction (GO:0000003); 6, biological regulation (GO:0065007); 7, response to
stimulus (GO:0050896); 8, developmental process (GO:0032502); 9, multicellular organismal process (GO:0032501); 10, biological adhesion
(GO:0022610); 11, metabolic process (GO:0008152); 12, immune system process (GO:0002376). b Protein class: 1 extracellular matrix protein
(PC00102); 2, protease (PC00190); 3, cytoskeletal protein (PC00085); 4, transporter (PC00227); 5, transmembrane receptor regulatory/adaptor
protein (PC00226); 6, transferase (PC00220); 7, oxidoreductase (PC00176); 8, lyase (PC00144); 9, cell adhesion molecule (PC00069); 10, ligase
(PC00142); 11, nucleic acid binding (PC00171); 12, signaling molecule (PC00207); 13, enzyme modulator (PC00095); 14, calcium-binding protein
(PC00060); 15, defense/immunity protein (PC00090); 16, hydrolase (PC00121); 17, transfer/carrier protein (PC00219); 18, membrane traffic protein
(PC00150); 19, phosphatase (PC00181); 20, transcription factor (PC00218); 21, chaperone (PC00072); 22, cell junction protein (PC00070); 23,
surfactant (PC00212); 24, structural protein (PC00211); 25, kinase (PC00137); 26, storage protein (PC00210); 27, receptor (PC00197); 28,
isomerase (PC00135)
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Table 1 Seventy protein candidates characterizing LPIA listed in increasing order of the Rsc (LPIA vs. MIA) values; the negatively larger the Rsc value of a given protein, the
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1 HIP000323690 Band 7 protein
family protein
Band7 protein family protein 2858 77 0 0 77 100.0 0.0 0.0 -5.816 -5.758 -4.482 2.33E-22 5.80E-22 1.67E-13
2 P01892 HLA-A HLA class I histocompatibility antigen,
A-2 alpha chain
365 34 0 0 34 100.0 0.0 0.0 -4.663 -4.605 -3.329 3.75E-10 5.59E-10 2.94E-06
3 Q15233 NONO Non-POU domain-containing
octamer-binding protein
471 32 0 6 38 84.2 0.0 15.8 -4.579 -1.984 -3.244 1.38E-09 9.10E-05 6.39E-06
4 P31948 STIP1 Stress-induced-phosphoprotein 1 543 27 0 5 32 84.4 0.0 15.6 -4.344 -1.963 -3.009 3.63E-08 3.43E-04 4.45E-05
5 P10253 GAA Lysosomal alpha-glucosidase 952 26 0 0 26 100.0 0.0 0.0 -4.292 -4.233 -2.957 6.99E-08 9.48E-08 6.57E-05
6 Q07065 CKAP4 Cytoskeleton-associated protein 4 602 24 0 5 29 82.8 0.0 17.2 -4.181 -1.801 -2.847 2.58E-07 1.43E-03 1.43E-04
7 P17858 PFKL 6-phosphofructokinase, liver type 780 22 0 2 24 91.7 0.0 8.3 -4.062 -2.625 -2.727 9.55E-07 9.43E-05 3.11E-04
8 Q07960 ARHGAP1 Rho GTPase-activating protein 1 439 20 0 0 20 100.0 0.0 0.0 -3.932 -3.874 -2.598 3.53E-06 4.47E-06 6.77E-04
9 P06865 HEXA Beta-hexosaminidase subunit alpha 529 19 0 0 19 100.0 0.0 0.0 -3.863 -3.804 -2.528 6.80E-06 8.49E-06 9.99E-04
10 P53007 SLC25A1 Tricarboxylate transport protein,
mitochondrial
311 18 0 0 18 100.0 0.0 0.0 -3.790 -3.731 -2.455 1.31E-05 1.61E-05 1.47E-03
11 P36871 PGM1 Phosphoglucomutase-1 562 18 0 0 18 100.0 0.0 0.0 -3.790 -3.731 -2.455 1.31E-05 1.61E-05 1.47E-03
12 A0A0A6YYG9 ARPC4-TTLL3 ARPC4-TTLL3 fusion protein 625 18 0 0 18 100.0 0.0 0.0 -3.790 -3.731 -2.455 1.31E-05 1.61E-05 1.47E-03
13 Q96HE7 ERO1L ERO1-like protein alpha 468 16 0 0 16 100.0 0.0 0.0 -3.631 -3.573 -2.296 4.84E-05 5.84E-05 3.21E-03
14 Q02218 OGDH 2-oxoglutarate dehydrogenase,
mitochondrial
1023 16 0 1 17 94.1 0.0 5.9 -3.631 -2.725 -2.296 4.84E-05 5.45E-04 3.21E-03
15 P58107 EPPK1 Epiplakin 5090 15 0 0 15 100.0 0.0 0.0 -3.545 -3.487 -2.210 9.32E-05 1.11E-04 4.75E-03
16 P49588 AARS Alanine–tRNA ligase, cytoplasmic 968 15 0 0 15 100.0 0.0 0.0 -3.545 -3.487 -2.210 9.32E-05 1.11E-04 4.75E-03
17 P16615 ATP2A2 Sarcoplasmic/endoplasmic
reticulum calcium ATPase 2
997 15 0 0 15 100.0 0.0 0.0 -3.545 -3.487 -2.210 9.32E-05 1.11E-04 4.75E-03
18 P62873 GNB1 Guanine nucleotide-binding protein
G(I)/G(S)/G(T) subunit beta-1
340 14 0 0 14 100.0 0.0 0.0 -3.453 -3.395 -2.119 1.80E-04 2.11E-04 7.01E-03
19 O43760 SYNGR2 Synaptogyrin-2 224 14 0 0 14 100.0 0.0 0.0 -3.453 -3.395 -2.119 1.80E-04 2.11E-04 7.01E-03
20 O60701 UGDH UDP-glucose 6-dehydrogenase 494 12 0 0 12 100.0 0.0 0.0 -3.250 -3.192 -1.916 6.66E-04 7.66E-04 1.53E-02
21 Q5T2N8 ATAD3C ATPase family AAA domain-containing
protein 3C
411 11 0 0 11 100.0 0.0 0.0 -3.137 -3.079 -1.802 1.28E-03 1.46E-03 2.27E-02
22 P46782 RPS5 40S ribosomal protein S5 204 11 0 0 11 100.0 0.0 0.0 -3.137 -3.079 -1.802 1.28E-03 1.46E-03 2.27E-02
23 Q8NBJ7 SUMF2 Sulfatase-modifying factor 2 301 11 0 2 13 84.6 0.0 15.4 -3.137 -1.700 -1.802 1.28E-03 3.46E-02 2.27E-02











Table 1 Seventy protein candidates characterizing LPIA listed in increasing order of the Rsc (LPIA vs. MIA) values; the negatively larger the Rsc value of a given protein, the
greater its expression level in LPIA compared with MIA and AIS (Continued)
25 P46783 RPS10 40S ribosomal protein S10 165 10 0 0 10 100.0 0.0 0.0 -3.014 -2.956 -1.679 2.48E-03 2.78E-03 3.36E-02
26 P17516 AKR1C4 Aldo-keto reductase family 1 member C4 323 10 0 0 10 100.0 0.0 0.0 -3.014 -2.956 -1.679 2.48E-03 2.78E-03 3.36E-02
27 P15531 NME1 Nucleoside diphosphate kinase A 152 10 0 0 10 100.0 0.0 0.0 -3.014 -2.956 -1.679 2.48E-03 2.78E-03 3.36E-02
28 P15428 HPGD 15-hydroxyprostaglandin
dehydrogenase [NAD(+)]
266 10 0 0 10 100.0 0.0 0.0 -3.014 -2.956 -1.679 2.48E-03 2.78E-03 3.36E-02
29 O43776 NARS Asparagine–tRNA ligase, cytoplasmic 548 10 0 0 10 100.0 0.0 0.0 -3.014 -2.956 -1.679 2.48E-03 2.78E-03 3.36E-02
30 P68036 UBE2L3 Ubiquitin-conjugating enzyme E2 L3 154 9 0 0 9 100.0 0.0 0.0 -2.880 -2.821 -1.545 4.78E-03 5.30E-03 4.97E-02
31 P54802 NAGLU Alpha-N-acetylglucosaminidase 743 9 0 0 9 100.0 0.0 0.0 -2.880 -2.821 -1.545 4.78E-03 5.30E-03 4.97E-02
32 P11586 MTHFD1 C-1-tetrahydrofolate synthase, cytoplasmic 935 9 0 0 9 100.0 0.0 0.0 -2.880 -2.821 -1.545 4.78E-03 5.30E-03 4.97E-02
33 P02790 HPX Hemopexin 462 9 0 0 9 100.0 0.0 0.0 -2.880 -2.821 -1.545 4.78E-03 5.30E-03 4.97E-02
34 A8MWD9 SNRPF Small nuclear ribonucleoprotein G-like protein 76 9 0 0 9 100.0 0.0 0.0 -2.880 -2.821 -1.545 4.78E-03 5.30E-03 4.97E-02
35 Q9Y3U8 RPL36 60S ribosomal protein L36 105 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
36 Q14247 CTTN Src substrate cortactin 634 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
37 P62491 RAB11A Ras-related protein Rab-11A 216 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
38 P56192 MARS Methionine–tRNA ligase, cytoplasmic 900 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
39 P12830 CDH1 Cadherin-1 882 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
40 P05166 PCCB Propionyl-CoA carboxylase beta chain, mitochondrial 559 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
41 O75347 TBCA Tubulin-specific chaperone A 108 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
42 O43684 BUB3 Mitotic checkpoint protein BUB3 328 8 0 0 8 100.0 0.0 0.0 -2.732 -2.673 -1.397 9.22E-03 1.01E-02 7.37E-02
43 Q9UM22 EPDR1 Mammalian ependymin-related protein 1 224 7 0 0 7 100.0 0.0 0.0 -2.567 -2.508 -1.232 1.78E-02 1.93E-02 1.09E-01
44 Q14376 GALE UDP-glucose 4-epimerase 348 7 0 0 7 100.0 0.0 0.0 -2.567 -2.508 -1.232 1.78E-02 1.93E-02 1.09E-01
45 P48637 GSS Glutathione synthetase 474 7 0 0 7 100.0 0.0 0.0 -2.567 -2.508 -1.232 1.78E-02 1.93E-02 1.09E-01
46 P47897 QARS Glutamine–tRNA ligase 775 7 0 0 7 100.0 0.0 0.0 -2.567 -2.508 -1.232 1.78E-02 1.93E-02 1.09E-01
47 P15941 MUC1 Mucin-1 475 7 0 0 7 100.0 0.0 0.0 -2.567 -2.508 -1.232 1.78E-02 1.93E-02 1.09E-01
48 O60763 USO1 General vesicular transport factor p115 962 7 0 0 7 100.0 0.0 0.0 -2.567 -2.508 -1.232 1.78E-02 1.93E-02 1.09E-01
49 P46977 STT3A Dolichyl-diphosphooligosaccharide–protein
glycosyltransferase subunit STT3A
705 12 1 0 13 92.3 7.7 0.0 -2.402 -3.192 -1.916 4.91E-03 7.66E-04 1.53E-02
50 O43488 AKR7A2 Aflatoxin B1 aldehyde reductase member 2 358 12 1 1 14 85.7 7.1 7.1 -2.402 -2.344 -1.916 4.91E-03 5.59E-03 1.53E-02
51 Q9Y3I0 C22orf28 tRNA-splicing ligase RtcB homolog 505 6 0 0 6 100.0 0.0 0.0 -2.380 -2.322 -1.045 3.45E-02 3.70E-02 1.63E-01
52 Q9NRV9 HEBP1 Heme-binding protein 1 189 6 0 0 6 100.0 0.0 0.0 -2.380 -2.322 -1.045 3.45E-02 3.70E-02 1.63E-01
53 Q9BPW8 NIPSNAP1 Protein NipSnap homolog 1 284 6 0 0 6 100.0 0.0 0.0 -2.380 -2.322 -1.045 3.45E-02 3.70E-02 1.63E-01
54 P49419 ALDH7A1 Alpha-aminoadipic semialdehyde
dehydrogenase
539 6 0 0 6 100.0 0.0 0.0 -2.380 -2.322 -1.045 3.45E-02 3.70E-02 1.63E-01











Table 1 Seventy protein candidates characterizing LPIA listed in increasing order of the Rsc (LPIA vs. MIA) values; the negatively larger the Rsc value of a given protein, the
greater its expression level in LPIA compared with MIA and AIS (Continued)
56 P14868 DARS Aspartate–tRNA ligase, cytoplasmic 501 6 0 0 6 100.0 0.0 0.0 -2.380 -2.322 -1.045 3.45E-02 3.70E-02 1.63E-01
57 P00533 EGFR Epidermal growth factor receptor 705 6 0 0 6 100.0 0.0 0.0 -2.380 -2.322 -1.045 3.45E-02 3.70E-02 1.63E-01
58 Q02252 ALDH6A1 Methylmalonate-semialdehyde dehydrogenase
[acylating], mitochondrial
535 29 4 9 42 69.0 9.5 21.4 -2.372 -1.348 -3.108 2.84E-05 4.68E-03 2.05E-05
59 Q99829 CPNE1 Copine-1 537 26 4 7 37 70.3 10.8 18.9 -2.221 -1.510 -2.957 1.38E-04 3.51E-03 6.57E-05
60 Q15363 TMED2 Transmembrane emp24
domain-containing protein 2
201 10 1 0 11 90.9 9.1 0.0 -2.166 -2.956 -1.679 1.57E-02 2.78E-03 3.36E-02
61 P35221 CTNNA1 Catenin alpha-1 906 28 5 10 43 65.1 11.6 23.3 -2.072 -1.165 -3.059 1.61E-04 1.31E-02 3.02E-05
62 O75340 PDCD6 Programmed cell death protein 6 191 30 6 3 39 76.9 15.4 7.7 -1.953 -2.665 -3.155 1.78E-04 5.33E-06 1.39E-05
63 O00764 PDXK Pyridoxal kinase 312 11 2 2 15 73.3 13.3 13.3 -1.759 -1.700 -1.802 3.11E-02 3.46E-02 2.27E-02
64 P13667 PDIA4 Protein disulfide-isomerase A4 645 70 18 26 114 61.4 15.8 22.8 -1.735 -1.174 -4.346 1.64E-07 7.79E-05 2.52E-12
65 Q9NTX5 ECHDC1 Ethylmalonyl-CoA decarboxylase 307 28 7 1 36 77.8 19.4 2.8 -1.671 -3.487 -3.059 1.17E-03 4.05E-07 3.02E-05
66 Q7Z4W1 DCXR L-xylulose reductase 244 23 7 0 30 76.7 23.3 0.0 -1.400 -4.065 -2.788 9.91E-03 6.51E-07 2.11E-04
67 Q9Y2Q3 GSTK1 Glutathione S-transferase kappa 1 226 14 4 3 21 66.7 19.0 14.3 -1.383 -1.629 -2.119 4.58E-02 2.20E-02 7.01E-03
68 P49748 ACADVL Very long-chain specific acyl-CoA
dehydrogenase, mitochondrial
655 30 10 12 52 57.7 19.2 23.1 -1.319 -1.024 -3.155 4.98E-03 2.05E-02 1.39E-05
69 P42224 STAT1 Signal transducer and activator
of transcription 1- alpha/beta
750 16 5 0 21 76.2 23.8 0.0 -1.309 -3.573 -2.296 4.13E-02 5.84E-05 3.21E-03











including pancreas, lung, ovary, breast and prostate,
frequently suggesting its association with tumor pro-
gression and metastasis [13, 14, 26–30]. The HYOU1
protein (hypoxia up-regulated 1, alternatively known as
Orp150), belonging to the heat shock protein 70 family,
demonstrated its increased expression in prostate, blad-
der and invasive breast cancer, is suggested to be asso-
ciated with tumor invasiveness [31].
Protein-protein network analysis of expressed proteins
Network analysis of significant proteins is also helpful to
understand how they interplay with other key proteins
and pathways. In this study the network analysis of
protein-protein interaction was performed by utilizing the
STRING database version 10 [32, 33]. Therein only exper-
iments, databases and text mining were utilized to avoid
less confident predicted interactions. The STRING PPI
networks were obtained by applying 70 proteins expressed
significantly to LPIA (given in Table 1) and shown in Fig. 2
(also given as Additional file 2: Figure S1). The STRING
PPI networks obtained for AIS and MIA are provided as
Additional file 3: Figure S2 and Additional file 4: Figure S3.
Figure 3 illustrates results of the STRING gene set en-
richments (GSEs) for LPIA, MIA, and AIS obtained
against cancer related KEGG pathways, which were eluci-
dated with their significance rank p < 0.05 after correction
by false discovery rate (FDR). All results are provided in
Additional file 1: Table S4. Enrichments on AIS indicated
the strong association with pathways of focal adhesion
(p = 2.69 × 10−16), adherens junction (p = 6.45 × 10−12) and
leukocyte transendothelial migration (p = 9.79 × 10−13).
MIA was found to be associated with PI3K-Akt signaling
(p = 8.25 × 10−6) and predominantly with proteoglycans in
cancer (p = 3.99 × 10−17). In contrast, LPIA was associated
broadly with numerous cancer-related pathways which in-
cluded proteoglycans in cancer (p = 5.94 × 10−5), ErbB sig-
naling (p = 2.99 × 10−3), Ras signaling (p = 5.77 × 10−3),
Rap1 signaling (p = 9.72 × 10−4), chemokine signaling
(p = 7.23 × 10−5), and HIF-1 signaling (p = 5.77 × 10−3).
Proteoglycans are known to be important molecular ef-
fectors of cell surface and pericellular microenvironments
and to have multiple functions in cancer and angiogenesis
by interacting with both ligands and receptors that regulate
neoplastic growth and neovascularization [34]. Molecules
participating in the proteoglycan-related cancer pathway
were denoted by red circles in Additional file 3: Figure S2.
The ErbB signaling pathway is associated with many cancer
pathways. The ErbB family belong epidermal growth factor
receptors which play an important role in tumor growth.
Over-expression of EGFR occurs around 60 % of non-small
cell lung cancer (NSCLC), in which adenocarcinoma has
the higher frequency [35]. Hypoxia-inducible factors (HIFs)
regulate the transcription of genes that mediate the re-
sponse to hypoxia (reduced O2 availability) [36]. It is
considered that diverse products of HIF-1 action such as
induction of the Met protein, hepatocyte growth factor
(HGF), followed by Met receptor activation may result in
the poor prognosis attached to hypoxic tumors, which in-
deed turn out to be more aggressive that their well-
oxygenerated counterparts. Molecules participating in the
ErbB and HIF-1 signaling pathways were denoted by or-
ange and red circles, respectively, in Fig. 2. Numerous clin-
ical data demonstrated that increased levels of HIF-1
proteins consequenced a poor prognosis and increased
patient mortality in many different human cancers in-
cluding NSCLC [37].
Conclusion
Former localized BAC (≦2 cm) lesions have been histo-
logically classified into types A, B and C by Noguchi et
al. based on finding of local cancer progression [38].
These lesions, now identified as AIS, MIA or LPIA usu-
ally show focal ground-glass opacity (GGO) on chest
HRCT (high resolution computed tomography). Gener-
ally, AIS shows pure GGO, and representative MIA and
LPIA lesions show GGO with some intratumoral areas
of collapsed shadow suggesting invasion. There are mul-
tiple studies [39, 40] describing that limited lung resec-
tion including wedge resection or segmentectomy can
cure early adenocarcinomas showing pure GGO. From
histologic and radiologic points of view, it is hypothe-
sized that preinvasive AIS progresses to the invasive le-
sions MIA and LPIA sequentially. Postsurgical 5-year
recurrence-free survival rates for AIS and MIA are 100 %,
while these for LPIA ranged 71.9 to 93.8 % [8–10].
The molecular biological background predisposing the
worse prognosis of LPIA compared with AIS and MIA
may be in part due to the forms of altered protein ex-
pressions found in our present study. Proteins appearing
in the step from AIS to MIA are probably important at
the initial step of microinvasion. As LPIA prepares char-
acteristics of matured lung cancer, it is reasonable that
LPIA expresses a variety of proteins associated with can-
cer invasion. We believe that some of these proteins are
candidates for molecular target therapy to suppress local
invasion or distant metastases.
In the new adenocarcinoma subtyping, prognoses of solid
or micropapillary predominant invasive adenocarcinomas
were reported to be apparently worse than these of other
subtypes including lepidic type adenocarcinomas [10, 41, 42].
We imagine that in the future comparative proteomic
analyses such as that presented here will contribute to elu-
cidate protein expressions determining malignant grade of
various lung adenocarcinoma subtypes, which will further
provide important knowledge to understand the carcino-
genetic process and tumor lineages of lung adenocarcin-
omas for the benefit of patients with more efficient
diagnosis and treatment of these tumors.
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Method
Ethics approval
The study protocol conformed to the principles of the Dec-
laration of Helsinki. All patients were provided with informed
consent and the study protocol was approved by Tokyo
Medical University Hospital institutional ethics committee.
FFPE tissues and sample preparation
Surgically removed lung tissues were fixed with a buff-
ered formalin solution containing 10 – 15-% methanol,
and embedded by a conventional method. Archived par-
affin blocks of formalin-fixed adenocarcinoma tissues
obtained from cases of AIS (n = 3), MIA (n = 3), and
Fig. 2 The high-resolution evidence-view of STRING PPI networks obtained on LPIA by using 70 proteins significantly expressed (listed in Table 1),
which were generated using default setting in network depth of 50 interactions under medium confidence (0.4) and standard criteria for linkage
only with experiments, databases, and textmining
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LPIA (n = 3), which were retrieved with the approval from
Ethical Committee of Tokyo Medical University Hospital
(Acception No. 1964). Patients’ characteristics are listed in
Table 2. Paraffin blocks were cut into 4-μm sections for
diagnosis and 10-μm sections for proteomics. The 10-μm
sections were stained with only haematoxylin. Three pa-
thologists (M.N., Y.K.) independently confirmed adenocar-
cinoma subtypes using the 4-μm sections stained with
haematoxylin-eosin (HE).
Laser capture and protein solubilization
Cancerous lesions were identified on serial tissue sections
stained with hematoxylin and eosin (HE). For proteomic
analysis, a 10-μm thick section prepared from the same
tissue block was attached onto DIRECTOR™ slides (Onco-
PlexDx, Rockville, MD, USA), de-paraffinized twice with
xylene for 5-min, rehydrated with graded ethanol solu-
tions and distilled water, and stained by hematoxylin.
Those slides were air-dried and subjected to laser micro-
dissection with a Leica LMD6000 (Leica Micro-systems
GmbH, Ernst-Leitz-Strasse, Wetzlar, Germany). At least
30,000 cells (8.17 ± 0.03 mm2) per a tissue were collected
directly into a 1.5-mL low-binding plastic tube. From indi-
vidual three types tissues non-cancerous lesions far from
tumors were also collect the same numbers of cells as the
pseudo-normal (pN) group (n = 3). Representative HE-
stained images of adenocarcinoma tissues of AIS, MIA
and LPIA were shown in Fig. 4 together with examples of
Fig. 3 Cancer-related pathways associated with AIS, MIA and LPIA, which were obtained by the STRING enrichment analysis under the statistical
significance of p <0.05
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targeted lesions before and after laser-microdissections
(LMD). Proteins were extracted and digested with trypsin
using Liquid Tissue™ MS Protein Prep kits (OncoPlexDx,
Rockville, MD, USA) according to the manufacturer’s
protocol [43].
Exploratory liquid chromatography-tandem mass
spectrometry
The digested samples were analyzed in triplicate and in
random order by liquid chromatography (LC)-tandem
mass spectrometry (MS/MS) using reverse-phase liquid
chromatography (RP-LC) interfaced with a LTQ-Orbitrap
XL hybrid mass spectrometer (Thermo Fisher Scientific,
Bremen, Germany) via a closed nano-electrospray device
(ADVANCE Captive Spray Source; AMR Inc. Japan). The
RP-LC system consisted of Paradigm MS4 (Michrom
Bioresources, USA), a peptide Cap-Trap cartridge (0.3 ×
5.0 mm) and a capillary separation column (an L-column
Micro of 0.1 × 150 mm packed with reverse phase L-C18
gels of 3 μm in diameter and 12-nm pore size, (CERI,
Tokyo, Japan)). An autosampler (HTC-PAL, CTC Analyt-
ics, Switzerland) loaded an aliquot of samples onto the
trap, which then was washed with solvent A (98 % distilled
water with 2 % acetonitrile and 0.1 % formic acid) for con-
centrating peptides on the trap and desalting. Subse-
quently, the trap was connected in series to the separation
column, and the whole columns were developed for
100 min with a linear acetonitrile concentration gradient
made from 5 to 35 % solvent B (10 % distilled water and
90 % acetonitrile containing 0.1 % formic acid) at the
flow-rate of 300 nL/min.
An LTQ was operated in the data-dependent MS/MS
mode to automatically acquire up to three successive MS/
MS scans in the centroid mode. The three most intense
precursor ions for these MS/MS scans could be selected
from a high-resolution MS spectrum (a survey scan) that
an Orbitrap previously acquired during a predefined short
time window in the profile mode at the resolution of
30,000 and the lock mass of m/z 536.1654 in the m/z
range of 350 to 1500. The sets of acquired high-resolution
MS and MS/MS spectra for peptides were converted to
single data files and they were merged into Mascot generic
format files for database searching.
Protein identification
To extract protein candidates characterizing lepidic type
adenocarcinoma from the shotgun proteomic datasets
experimentally acquired, consisting of 36 runs (triplicate
runs of 12 samples from 4 groups, AIS, MIA, LPIA, and
pseudo-normal, N), we have utilized a label-free spectral
counting approach for proteomic data analysis on pro-
tein identification and semi-quantitative comparison.
Tha mass spectral raw data were analyzed using the one-
path method of X! Tandem wth a k-score plugin in Trans-
Proteomic pipeline (TPP) [44, 45] against the combined
protein fasta file from Human-Invitational database (H-
InvDB) [46], RefSeq, and UniProtKB/Swiss-Prot appended
with reversed decoy sequences. Peptide mass tolerance was
10 ppm, fragment mass tolerance 0.5 Da, and up to two
missed cleavages and non-tryptic cleavage at one end of a
peptide were allowed. Methionine oxidation is considered
as variable modification. The output files from the search
engine were converted to the pepXML files and subjected
to peptide-spectrum match (PSM) posterior probability
calculation with PeptideProphet [47] and then to Protein-
Prophet for identification at the protein level in Trans-
proteomic pipeline (TPP) [44, 45].
Semi-quantitative comparison
For calculating spectral counts (SpCs) at the protein level,
triplicate X!Tandem [48] results for each patient were sim-
ultaneously analyzed with PeptideProphet and the single
Table 2 Patients’ characteristics
Patient number Age Sex CEA (ng/ml) Location Tumor size on CT (mm) Histological type TNM classification EGFR mutation
2 55 M 3.9 Rt.S1 11 pseudo-Normala AIS T1aN0M0 Unkown
4 59 W 8.1 Lt.S1 + 2 15 pseudo-Normala LPIA T1bN0M0 Unkown
9 55 W 5.3 Rt.S4 37 pseudo-Normala LPIA T1bN0M0 Unkown
1 63 W 1.9 Rt.S2 15 Adenocarcinoma AIS T1aN0M0 Unkown
2 55 M 3.9 Rt.S1 11 Adenocarcinoma AIS T1aN0M0 Unkown
3 56 W 2 Lt.S8 10 Adenocarcinoma AIS T1aN0M0 Unkown
4 59 W 8.1 Lt.S3 28 Adenocarcinoma MIA T1bN0M0 Unkown
5 73 W 5.4 Rt.S5 25 Adenocarcinoma MIA T1bN0M0 Unkown
6 74 W 1.5 Lt.S3 25 Adenocarcinoma MIA T1bN0M0 L858R
7 78 W 1.5 Rt.S3 37 Adenocarcinoma LPIA T2aN0M0 L858R
8 72 W 0.6 Rt.S1 51 Adenocarcinoma LPIA T2aN0M0 Unkown
9 55 W 5.3 Rt.S4 37 Adenocarcinoma LPIA T1bN0M0 Unkown
alesions judged pathologically as non-cancerous regions adjacent to tumors
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output file was subjected to ProteinProphet [49]. In
addition, all PeptideProphet results were simultaneously an-
alyzed with ProteinProphet. Then, all PeptideProphet and
ProtinProphet results were used for extracting significant
proteins and computing SpCs with Abacus [20] using the
following thresholds: maxiniProb threshold = 0.99 for the
minimum PeptideProphet score, and Combined File Prob
threshold = 0.9 for the minimum ProteinProphet score in
the combined file.
Fold changes of expressed proteins in the base 2 logarith-
mic scale (RSC) were calculated using spectral counting as
described [15]. Proteins expressed significantly between two
groups were chosen so that their RSC satisfy >1 or < −1,
which correspond to their fold changes >2 or <0.5, and
p-value < 0.05 in G-test [19]. Although G-test does not re-
quire replicates, spectral counts for each protein from trip-
licates were pooled and used for G-statistic calculation
using a two-way contingency table arranged in two rows
for a target protein and any other proteins, and two col-
umns for cancer groups on an Excel macro. The Yates cor-
rection for continuity was applied to the 2 × 2 tables. The
correction could enable us to handle the data containing
small spectral counts including zero.
Network analysis of protein-protein interactions
Network analysis of protein-protein interactions was car-
ried out by using the Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) database version 10
[32, 33], in which nodes are proteins and edges are the
predicted functional associations based on primary data-
bases comprising of KEGG and GO, and primary litera-
ture. STRING can predict these interactions based on
neighbourhood, gene fusion products, homology and
similarity of coexpression patterning, experiments, data-
bases and textmining. Network interaction scores for each
node are expressed as a joint probability derived from cu-
rated databases of experimental information, textmining
and computationally predicted by genetic proximity [32].
In this study, STRING networks were calculated under
the criteria for linkage only with experiments, databases,
and textmining with the default settings - medium confi-
dence score: 0.400, network depth: 0 and up to 50
interactions.
Additional files
Additional file 1: Table S1. Proteins characteristic to AIS, which were
under p < 0.05 (AIS vs LPIA), Rsc > 1 (LPIA vs. AIS), and [AIS] greater than
[LPIA] and [MIA]. Table S2. Proteins characteristic to MIA, which were
under p < 0.05 (MIA vs LPIA), Rsc > 1 (LPIA vs. MIA), and [MIA] greater
than [LPIA] and [AIS]. Table S3. The list of total 840 proteins identified.
Table S4. The STRING network enrichment results on KEGG pathways.
Additional file 2: Figure S1. The high-resolution evidence-view of
STRING PPI networks obtained on LPIA by using 70 proteins significantly
expressed (listed in Table 1), which were generated using default setting
in network depth of 50 interactions under medium confidence (0.4) and
standard criteria for linkage only with experiments, databases, and text
mining.
Additional file 3: Figure S2. The high-resolution evidence-view of




Fig. 4 Representative HE-stained images of a) adenocarcinoma in
situ (AIS), b) minimally invasive adenocarcinoma (MIA), and c) lepidic
predominant invasive adenocarcinoma (LPIA). In AIS, no foci of
invasion or scarring could not be seen, and atypical pneumocytes
were proliferating along the slightly thickened alveolar wall. In MIA,
showing a small area of invasion (<0.5 cm), tumor cells grew mostly
in lepidic pattern along the surface of alveolar walls. In LPIA, showing a
larger area of invasion (≧0.5 cm), type II pneumocytes and Clara cells
were proliferating along the surface of thickened alveolar walls.
Alveolar epitheliums are substituted in tumor cells, together with
examples of targeted lesions before and after
laser-microdissections (LMD)
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expressed (listed in Additional file 1: Table S1), which were generated
using default setting in network depth of 50 interactions under medium
confidence (0.4) and standard criteria for linkage only with experiments,
databases, and text mining.
Additional file 4: Figure S3. The high-resolution evidence-view of
STRING PPI networks obtained on MIA by using 15 proteins significantly
expressed (listed in Additional file 1: Table S2), which were generated
using default setting in network depth of 50 interactions under medium
confidence (0.4) and standard criteria for linkage only with experiments,
databases, and text mining.
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